AstraZeneca PLC is set to report its latest quarterly earnings on Tuesday, April 28th, with a consensus EPS estimate of $2.57.
Today, AstraZeneca's stock price stands at $186.66, down by 85 cents (-0.453%) from the previous close of $187.51. The trading volume is at $1.40 million, 65.65% of the average.
AstraZeneca has seen a six-day streak of declining prices, with a total absolute change of -$18.14 (-8.86%) starting from $204.8.
The company's most recent earnings report on Monday, February 9th, revealed a consensus EPS estimate of 1.09.
AstraZeneca offers a forward dividend yield of 4.6%, with a dividend per share of $2.15 and a total trailing twelve months dividend per share of $4.84.
The company reported a free cash flow of $1.38 billion and a net change in cash of -$2.41 billion, ending the period with $5.72 billion in cash.
AstraZeneca generated $15.50 billion in revenue, with a gross profit of $12.38 billion and a net income of $2.33 billion. The EPS was $3.02.
Key ratios include a net profit margin of 15%, return on equity of 4.78%, and a price-to-earnings ratio of 30.93.
The company holds $5.71 billion in cash and cash equivalents, with total assets amounting to $114 billion and total liabilities at $65.36 billion.
This real-time financial snapshot provides insights into AstraZeneca PLC's current standing and performance metrics.
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.